Center for Clinical Studies

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)4 trials
• Psoriasis4 trials
• Vitiligo4 trials
• Alopecia areata2 trials
• Obesity1 trial

Phase

• Phase 37 trials
• Phase 25 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed7 trials
• Recruiting4 trials
• Active, not recruiting3 trials

Lead sponsor

• Eli Lilly and Company4 trials
• Janssen Research & Development, LLC3 trials
• Pfizer2 trials
• Amgen1 trial
• Apollo Therapeutics Ltd1 trial
• and 3 more

Running trials

• Recruiting

  A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

  NCT07431177· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Perla Rivas

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

  NCT07223229· Phase 2· Elixiron Immunotherapeutics (Hong Kong) Ltd.· Source

  Contact: Mario Guerrero Site Coordinator

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Recruiting

  A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  NCT06857942· Phase 4· Eli Lilly and Company· Source

  Contact: Stephen Tyring (principal investigator)

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  NCT06113445· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Vitiligo2 recruiting
• Alopecia areata1 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

  NCT06436183· Phase 2· Apollo Therapeutics Ltd· Source

• Completed

  A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06176768· Phase 2· Eli Lilly and Company· Source

• Completed

  Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

  NCT06039189· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05633355· Phase 3· Amgen· Source

• Completed

  Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

  NCT05272150· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

  NCT03570749· Phase 2/3· Eli Lilly and Company· Source